vs

Side-by-side financial comparison of PUMA BIOTECHNOLOGY, INC. (PBYI) and TRANSCAT INC (TRNS). Click either name above to swap in a different company.

TRANSCAT INC is the larger business by last-quarter revenue ($83.9M vs $75.5M, roughly 1.1× PUMA BIOTECHNOLOGY, INC.). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 25.6%). PUMA BIOTECHNOLOGY, INC. produced more free cash flow last quarter ($14.4M vs $9.5M). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 8.7%).

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

Transcat Inc is a leading provider of calibration and measurement compliance solutions, as well as a distributor of professional test and measurement instruments. It serves core sectors including life sciences, aerospace, industrial manufacturing, energy and utilities, with primary operations across the United States and Canada, helping clients meet regulatory and operational accuracy requirements.

PBYI vs TRNS — Head-to-Head

Bigger by revenue
TRNS
TRNS
1.1× larger
TRNS
$83.9M
$75.5M
PBYI
Growing faster (revenue YoY)
PBYI
PBYI
+2.1% gap
PBYI
27.7%
25.6%
TRNS
More free cash flow
PBYI
PBYI
$4.9M more FCF
PBYI
$14.4M
$9.5M
TRNS
Faster 2-yr revenue CAGR
PBYI
PBYI
Annualised
PBYI
31.3%
8.7%
TRNS

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
PBYI
PBYI
TRNS
TRNS
Revenue
$75.5M
$83.9M
Net Profit
$-1.1M
Gross Margin
69.3%
30.1%
Operating Margin
22.7%
0.1%
Net Margin
-1.3%
Revenue YoY
27.7%
25.6%
Net Profit YoY
-146.7%
EPS (diluted)
$0.26
$-0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PBYI
PBYI
TRNS
TRNS
Q4 25
$75.5M
$83.9M
Q3 25
$54.5M
$82.3M
Q2 25
$52.4M
$76.4M
Q1 25
$46.0M
$77.1M
Q4 24
$59.1M
$66.8M
Q3 24
$80.5M
$67.8M
Q2 24
$47.1M
$66.7M
Q1 24
$43.8M
$70.9M
Net Profit
PBYI
PBYI
TRNS
TRNS
Q4 25
$-1.1M
Q3 25
$8.8M
$1.3M
Q2 25
$5.9M
$3.3M
Q1 25
$3.0M
$4.5M
Q4 24
$2.4M
Q3 24
$20.3M
$3.3M
Q2 24
$-4.5M
$4.4M
Q1 24
$-4.8M
$6.9M
Gross Margin
PBYI
PBYI
TRNS
TRNS
Q4 25
69.3%
30.1%
Q3 25
77.7%
32.5%
Q2 25
76.5%
33.8%
Q1 25
77.1%
33.6%
Q4 24
76.4%
29.5%
Q3 24
63.9%
31.3%
Q2 24
77.4%
34.0%
Q1 24
75.5%
33.9%
Operating Margin
PBYI
PBYI
TRNS
TRNS
Q4 25
22.7%
0.1%
Q3 25
17.6%
4.3%
Q2 25
12.7%
7.0%
Q1 25
8.7%
9.0%
Q4 24
22.6%
3.1%
Q3 24
27.4%
5.5%
Q2 24
-4.6%
7.6%
Q1 24
-5.3%
13.0%
Net Margin
PBYI
PBYI
TRNS
TRNS
Q4 25
-1.3%
Q3 25
16.2%
1.5%
Q2 25
11.2%
4.3%
Q1 25
6.5%
5.8%
Q4 24
3.5%
Q3 24
25.2%
4.8%
Q2 24
-9.6%
6.6%
Q1 24
-11.0%
9.7%
EPS (diluted)
PBYI
PBYI
TRNS
TRNS
Q4 25
$0.26
$-0.12
Q3 25
$0.17
$0.14
Q2 25
$0.12
$0.35
Q1 25
$0.06
$0.49
Q4 24
$0.40
$0.25
Q3 24
$0.41
$0.35
Q2 24
$-0.09
$0.48
Q1 24
$-0.10
$0.81

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PBYI
PBYI
TRNS
TRNS
Cash + ST InvestmentsLiquidity on hand
$97.5M
$3.5M
Total DebtLower is stronger
$22.7M
Stockholders' EquityBook value
$130.3M
$296.8M
Total Assets
$216.3M
$472.9M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PBYI
PBYI
TRNS
TRNS
Q4 25
$97.5M
$3.5M
Q3 25
$94.4M
$5.1M
Q2 25
$96.0M
$1.9M
Q1 25
$93.2M
$1.5M
Q4 24
$101.0M
$4.6M
Q3 24
$96.7M
$23.8M
Q2 24
$96.8M
$22.7M
Q1 24
$107.2M
$35.2M
Total Debt
PBYI
PBYI
TRNS
TRNS
Q4 25
$22.7M
Q3 25
$34.0M
Q2 25
$45.3M
Q1 25
$56.7M
Q4 24
$68.0M
Q3 24
$79.3M
Q2 24
$90.7M
Q1 24
$102.0M
Stockholders' Equity
PBYI
PBYI
TRNS
TRNS
Q4 25
$130.3M
$296.8M
Q3 25
$115.3M
$295.4M
Q2 25
$104.7M
$292.5M
Q1 25
$97.1M
$286.9M
Q4 24
$92.1M
$281.1M
Q3 24
$71.1M
$268.8M
Q2 24
$48.5M
$262.3M
Q1 24
$51.0M
$225.2M
Total Assets
PBYI
PBYI
TRNS
TRNS
Q4 25
$216.3M
$472.9M
Q3 25
$202.9M
$484.9M
Q2 25
$194.9M
$392.5M
Q1 25
$196.2M
$385.2M
Q4 24
$213.3M
$386.0M
Q3 24
$220.7M
$323.6M
Q2 24
$205.0M
$323.7M
Q1 24
$214.1M
$287.6M
Debt / Equity
PBYI
PBYI
TRNS
TRNS
Q4 25
0.17×
Q3 25
0.30×
Q2 25
0.43×
Q1 25
0.58×
Q4 24
0.74×
Q3 24
1.12×
Q2 24
1.87×
Q1 24
2.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PBYI
PBYI
TRNS
TRNS
Operating Cash FlowLast quarter
$14.4M
$12.1M
Free Cash FlowOCF − Capex
$14.4M
$9.5M
FCF MarginFCF / Revenue
19.1%
11.3%
Capex IntensityCapex / Revenue
0.0%
3.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$41.7M
$24.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PBYI
PBYI
TRNS
TRNS
Q4 25
$14.4M
$12.1M
Q3 25
$9.7M
$12.9M
Q2 25
$14.1M
$3.6M
Q1 25
$3.6M
$10.6M
Q4 24
$15.6M
$12.6M
Q3 24
$11.0M
$6.8M
Q2 24
$1.0M
$8.9M
Q1 24
$11.2M
$5.7M
Free Cash Flow
PBYI
PBYI
TRNS
TRNS
Q4 25
$14.4M
$9.5M
Q3 25
$9.7M
$8.4M
Q2 25
$14.1M
$-975.0K
Q1 25
$3.6M
$7.9M
Q4 24
$15.6M
$9.7M
Q3 24
$11.0M
$2.9M
Q2 24
$1.0M
$5.3M
Q1 24
$1.5M
FCF Margin
PBYI
PBYI
TRNS
TRNS
Q4 25
19.1%
11.3%
Q3 25
17.7%
10.3%
Q2 25
26.8%
-1.3%
Q1 25
7.7%
10.3%
Q4 24
26.4%
14.6%
Q3 24
13.7%
4.2%
Q2 24
2.1%
7.9%
Q1 24
2.2%
Capex Intensity
PBYI
PBYI
TRNS
TRNS
Q4 25
0.0%
3.2%
Q3 25
0.0%
5.4%
Q2 25
0.0%
6.0%
Q1 25
0.1%
3.5%
Q4 24
0.0%
4.3%
Q3 24
0.0%
5.8%
Q2 24
0.0%
5.5%
Q1 24
0.0%
5.9%
Cash Conversion
PBYI
PBYI
TRNS
TRNS
Q4 25
Q3 25
1.10×
10.15×
Q2 25
2.41×
1.11×
Q1 25
1.21×
2.38×
Q4 24
5.34×
Q3 24
0.54×
2.08×
Q2 24
2.02×
Q1 24
0.83×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons